Yurou Xing
Xuehu Wu2
Zhihui Li- 1Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- 2Department of Oncology, Minda Hospital of Hubei Minzu University, Enshi, China
- 3Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
- 4Head and Neck Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
by Xing Y, Wu X, Li Z and Wu X (2025) Front. Oncol. 15:1491918. doi: 10.3389/fonc.2025.1491918
In the published article, there was a mistake in the author affiliation.
Author Xuehu Wu was erroneously assigned to affiliation “Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China”. This affiliation has now been removed for author Xuehu Wu.
Affiliation “Department of Oncology, Minda Hospital of Hubei Minzu University, Enshi, China” was omitted for author Xuehu Wu. This affiliation has now been added for author Xuehu Wu.
Author Xin Wu was erroneously assigned to affiliation “Department of Oncology, Minda Hospital of Hubei Minzu University”. This affiliation has now been removed for author Xin Wu.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: anaplastic thyroid carcinoma, antiangiogenic drug, multimodal radiotherapy, immunotherapy, sustained remission anaplastic thyroid carcinoma
Citation: Xing Y, Wu X, Li Z and Wu X (2025) Correction: Case Report: Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab. Front. Oncol. 15:1649567. doi: 10.3389/fonc.2025.1649567
Received: 18 June 2025; Accepted: 20 June 2025;
Published: 03 July 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Xing, Wu, Li and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xin Wu, d3V4aW5kb2N0b3JAcXEuY29t